Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients

Garcia, Sara L.; Lauritsen, Jakob; Zhang, Zeyu; Bandak, Mikkel; Dalgaard, Marlene D.; Nielsen, Rikke L.; Daugaard, Gedske; Gupta, Ramneek

Published in:
Jnci Cancer Spectrum

Link to article, DOI:
10.1093/jncics/pkaa032

Publication date:
2020

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Garcia, S. L., Lauritsen, J., Zhang, Z., Bandak, M., Dalgaard, M. D., Nielsen, R. L., Daugaard, G., & Gupta, R. (2020). Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients. Jnci Cancer Spectrum, 4(3), [pkaa032]. https://doi.org/10.1093/jncics/pkaa032
Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients

Sara L. Garcia, MSc,1+,‡ Jakob Lauritsen, MD,2,*,‡ Zeyu Zhang, MSc,1,3+,‡ Mikkel Bandak, MD,2
Marlene D. Dalgaard, PhD,1 Rikke L. Nielsen, MSc,1,4 Gedske Daugaard, DMSc,2 Ramneek Gupta, PhD1

1Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark; 2Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark; 3Key Laboratory of Genetic Network Biology, Institute of Genetics and Developmental Biology, University of Chinese Academy of Sciences, Beijing, China; and 4Sino-Danish Center for Education and Research, Eastern Yanqihu campus, University of Chinese Academy of Sciences, Beijing, China

*Correspondence to: Jakob Lauritsen, MD, Department of Oncology, Copenhagen University Hospital, Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark (e-mail: jakob.lauritsen@regionh.dk).

‡Authors contributed equally to this work.

Abstract

Background: Cisplatin-based chemotherapy may induce nephrotoxicity. This study presents a random forest predictive model that identifies testicular cancer patients at risk of nephrotoxicity before treatment. Methods: Clinical data and DNA from saliva samples were collected for 433 patients. These were genotyped on Illumina HumanOmniExpressExome-8 v1.2 (964 193 markers). Clinical and genomics-based random forest models generated a risk score for each individual to develop nephrotoxicity defined as a 20% drop in isotopic glomerular filtration rate during chemotherapy. The area under the receiver operating characteristic curve was the primary measure to evaluate models. Sensitivity, specificity, and positive and negative predictive values were used to discuss model clinical utility. Results: Of 433 patients assessed in this study, 26.8% developed nephrotoxicity after bleomycin-etoposide-cisplatin treatment. Genomic markers found to be associated with nephrotoxicity were located at \( \text{NAT1} \), \( \text{NAT2} \), and the intergenic region of \( \text{CNTN6} \) and \( \text{CNTN4} \). These, in addition to previously associated markers located at \( \text{ERCC1} \), \( \text{ERCC2} \), and \( \text{SLC22A2} \), were found to improve predictions in a clinical feature–trained random forest model. Using only clinical data for training the model, an area under the receiver operating characteristic curve of 0.635 (95% confidence interval [CI] = 0.629 to 0.640) was obtained. Retraining the classifier by adding genomics markers increased performance to 0.731 (95% CI = 0.726 to 0.736) and 0.692 (95% CI = 0.688 to 0.696) on the holdout set. Conclusions: A clinical and genomics-based machine learning algorithm improved the ability to identify patients at risk of nephrotoxicity compared with using clinical variables alone. Novel genetics associations with cisplatin-induced nephrotoxicity were found for \( \text{NAT1} \), \( \text{NAT2} \), \( \text{CNTN6} \), and \( \text{CNTN4} \) that require replication in larger studies before application to clinical practice.

Standard treatment in patients with disseminated testicular cancer is chemotherapy consisting of bleomycin-etoposide-cisplatin (BEP). Cisplatin is also central in the treatment of many other solid tumors such as bladder, ovarian, and lung cancer (1). Treatment containing cisplatin has a wide range of side effects, one of which is nephrotoxicity (2,3). Cisplatin is excreted by the kidneys and may induce nephrotoxicity resulting in glomerular filtration rate (GFR) decline (4). Maintenance of sufficient renal function during treatment with chemotherapy is vital, and identification of patients at risk for developing nephrotoxicity could influence the treatment of choice if alternatives exist. Additionally, impaired renal function has been associated with increased risk of cardiovascular disease (5), which may pose a problem in long-term cancer survivors.

Previous studies have improved the understanding of molecular mechanisms of cisplatin-induced nephrotoxicity (6), and several candidate gene studies have identified single-nucleotide polymorphisms (SNPs) associated with cisplatin-induced nephrotoxicity (7–9). However, these studies were conducted with surrogate measures of GFR (creatinine clearance or estimated GFR) rather than measured GFR as outcome.

The scope of this study was 2-fold: first, to conduct a genome-wide association study (GWAS) using a linear model controlling for cisplatin dosage (high or normal) to identify new genetic variants associated with cisplatin-induced...
nephrotoxicity; and second, to investigate the utility of germline genetic markers together with clinical prognostic factors to predict nephrotoxicity using a random forest-recursive feature elimination algorithm. Patients treated for disseminated testicular cancer were chosen for this study because this patient group does not normally have comorbidity, which could influence renal function.

Methods

Patients

Patients were identified in the Danish Testicular Cancer-Late cohort (10), which includes 2572 Danish patients treated for testicular cancer from 1984 through 2007. Clinical features from 433 patients were originally extracted from hospital files as registered in the Danish Testicular Cancer database (Table 1). In 2014, all patients with measurements of renal function before and after treatment with BEP were invited to deliver a saliva sample for DNA analysis (Supplementary Figure 1, available online). Patients provided informed consent, and the study was approved by the regional ethical committee (H-2-2012-044) and the National Board of Data Protection (2012-41-0751).

Treatment and Renal Measurement

All 433 patients received 3 cycles or more of BEP. The majority received normal-dose cisplatin 20 mg/m² q3w, etoposide 100 mg/m² q3w, and bleomycin 15 IU/m² q1w, and 25 patients received double-dose cisplatin and etoposide: cisplatin 40 mg/m² q3w, etoposide 200 mg/m² q3w, and bleomycin 15 IU/m² q1w. Hydration remained uniform over time with 2 L isotonic saline before cisplatin and an additional 1-2 L after. Diuretics were administered only in special cases, and no magnesium was added to hydration. There was no predefined cutoff of renal function where patients would not receive cisplatin-based triplets; however, to ensure toxicity was related to treatment, only patients with a GFR greater than 90 mL/min/1.73m² before chemotherapy were included.

GFR was measured by the 1-sample 51Cr-ethylenediaminetetra acetic acid clearance technique using 2 samples 200 minutes after tracer injection and normalized to a body surface area (BSA) of 1.73 m².

Genomic Information

Genomic DNA was collected and purified using GeneFiX Saliva DNA Midi Kit from Isohelix (Harrietsham, UK). DNA samples were prepared at DTU Multi-Assay Core (Lyngby, Denmark) and genotyped at AROS Applied Biotechnology A/S (Aarhus, Denmark) using Illumina HumanOmniExpressExome-8 v1.2 chip (964 193 markers).

Genomic data were filtered using standard quality control steps (Supplementary Figure 2, available online). GWAS testing for single SNP association was conducted using PLINK (11).

Table 1. Comparison of baseline characteristics between affected (GFR high-drop) and nonaffected patients

| Characteristics                  | Affected, No. (%) | Nonaffected, No. (%) | \( p ^ {b} \) |
|---------------------------------|------------------|----------------------|----------------|
| No. of patients                 | 116 (26.8)       | 317 (73.2)           | .001           |
| **Clinical characteristics**    |                  |                      |                |
| Age, median (IQR)              | 34 (27-43)       | 30 (26-37)           | .001           |
| **BEP regimen**                |                  |                      | <.001          |
| Normal dose                    | 92 (79.3)        | 295 (93.4)           |                |
| Double dose                    | 24 (20.7)        | 21 (6.6)             |                |
| Unknown                        | 1                | 1                    |                |
| **GFR before treatment, median (IQR), mL/min/1.73 m²** | 128 (115-139) | 119 (110-131) | .001 |
| **GFR after treatment, median (IQR), mL/min/1.73 m²** | 88 (75-99) | 109 (100-119) | <.001 |
| **Cisplatin, median (IQR), mg/m²** | 400 (391-410) | 400 (300-400) | <.001 |
| **Treatment cycles**           |                  |                      |                |
| 3                              | 20 (17.2)        | 97 (30.6)            | <.001          |
| 4                              | 72 (62.1)        | 199 (62.8)           |                |
| 5 or more                      | 6 (5.2)          | 14 (4.4)             |                |
| High dose                      | 18 (15.5)        | 7 (2.2)              |                |
| **Histology**                  |                  |                      |                |
| Seminoma                       | 23 (19.8)        | 68 (21.5)            | .78            |
| Nonseminoma                    | 93 (80.2)        | 249 (78.5)           |                |
| **Prognostic group**           |                  |                      |                |
| Good                           | 71 (61.2)        | 277 (87.4)           | <.001          |
| Intermediate                   | 30 (25.9)        | 35 (11.0)            |                |
| Poor                           | 15 (12.9)        | 5 (1.6)              |                |
| **Stage**                      |                  |                      |                |
| Extragonadal                   | 15 (12.9)        | 15 (4.7)             | .87            |
| Stage Ia                       | 7 (6.0)          | 30 (9.6)             |                |
| Stage Ib                       | 22 (19.1)        | 80 (25.5)            |                |
| Stage Iic                      | 21 (18.1)        | 77 (24.5)            |                |
| Stage III                      | 23 (19.8)        | 42 (13.4)            |                |
| Stage IV                       | 28 (24.1)        | 70 (22.3)            |                |
| Unknown                        | —                | 3                    |                |

\( ^ {a} \)BEP = bleomycin-etoposide-cisplatin; GFR = glomerular filtration rate; IQR = interquartile range.

\( ^ {b} \)P values were calculated by 2-sided Mann-Whitney U test for continuous or ordinal characteristics. For “histology,” \( P \) value was calculated by \( \chi ^ 2 \) test.
(v1.9beta3), with the GFR decline after chemotherapy as the measure of toxicity and discretized cisplatin dosage as covariate with double-dose and normal-dose groups. The cutoff of 5 cycles was made to differentiate between normal and historically higher doses of cisplatin.

SNPs were annotated by ANNOVAR (v2015-06-17) (12) against the human reference genome hg19. Gene expression profiles were retrieved from GTExPortal (13).

We used a suggestive P value threshold of 1 × 10^{-5} (14) and a stringent threshold of 8.02 × 10^{-8} [Bonferroni corrected (15)].

In addition to the GWAS hits, 4 SNPs, rs11615 and rs3212986 (ERCC1), rs13161 (ERCC2), and rs316019 (SLC22A2), found in previous literature to be associated with cisplatin-induced nephrotoxicity (9), were added to the input feature search space in the machine learning modeling.

Clinical Information

The clinical features used as input feature variables in the machine learning model were age at time of treatment, GFR before treatment, cumulative cisplatin dose per square meter of BSA, normal dose vs double-dose BEP, number of treatment cycles, histology (seminoma vs nonseminoma), prognostic classification as per IGCCCG (16) and stage of the disease as surrogate for size of retroperitoneal tumor size, which was represented as 3 features in the model (details on Supplementary Methods, available online).

Statistical Analysis and Model Development

A random forest model (17), which identified different risk subgroups of GFR drop, was developed using SciKit-learn (18) in Python (v3.7.1). A GFR decline of more than 20% after chemotherapy was chosen as outcome to indicate a clinically significant change and to avoid selection of cases due to random variation. A 20% decline has been associated with, for example, cognitive deterioration (19) and risk of cardiovascular and all-cause mortality compared with those with stable GFR (20).

As a first stage, the predictive power of a model driven by clinical features only was established. In a second stage, genomic markers were added to the model.

From all 433 individuals, about 20% (78 individuals: 20 nephrotoxicity affected) of the data, with no missing values, was randomly separated ahead of time to be used as a holdout set. Therefore, for machine model training, we omitted those 78 individuals present on the holdout set and excluded individuals with missing data in either clinical or genomic data (Supplementary Figure 1, available online). Patients’ baseline characteristics in each of these sets are available in Supplementary Table 2 (available online).

Training and testing of the algorithm was performed with a 5 outer, 2 inner fold nested cross-validation (21,22) (Supplementary Figure 3, available online).

The sample-splitting process for training and testing cohorts was random and repeated 100 times. Area under the receiver operating characteristic curve (ROC-AUC) was used as the primary performance measure for model optimization.

A recursive backwards feature elimination approach was used for feature selection initiated with 10 clinical features and then reduced (23). To identify when the algorithm should stop removing features, a paired t test (level of statistical significance, P < .05) was calculated for each round of feature elimination on mean ROC-AUCs (Figure 1, A and B). A statistically significant AUC drop (P < .05) was indicative of an important feature being eliminated. All statistical tests were 2-sided. Details on model optimization and variable importance are described in the Supplementary Methods (available online).

The top-ranked clinical features constituted the baseline for adding prioritized SNPs from GWAS (17 SNPs) and the literature (4 SNPs), and feature selection was done using recursive backwards feature elimination approach.

Polygenic Risk Score (PRS)-Derived Models

We also calculated PRS-derived models weighted by effect sizes estimated by the GWAS using the R-Package PRSice (24). These were tested in the random forest models in place of individual SNPs. Two different approaches were used: the risks associated with all the 21 SNPs were combined to determine a PRS, and a PRS per gene was estimated.

Model Performances and Risk Groups

The primary reported performance was assessed with a 0.50 cutoff on the random forest model scores. In addition, to determine clinical applicability, we assessed different cutoffs on the random forest scores with a goal of 10% false discovery or omission rate (positive or negative predictive values >90%).

For the SNPs and clinical-based models from the best round, the split that had a representative ROC-AUC close to the mean was used to assess different cutoffs (25) (Supplementary Figure 4, available online).

Based on this, specific cutoffs for detection of 3 risk groups were used on the holdout set: a high-risk group for developing nephrotoxicity; a low-risk group for developing nephrotoxicity; and an intermediate group, which refers to individuals whose prediction is not adequately compelling to change the clinical decision.

Results

Study Population

Overall, 433 individuals (26.8% nephrotoxicity affected) were assessed in this study, with a median (interquartile range [IQR]) age of 34 (27-43) years for affected patients (N = 116) and 30 years (26-37) for nonaffected patients (N = 317). The majority received 3 or 4 cycles of BEP. Before treatment, the median (IQR) GFR (mL/min/1.73 m^2) was 128 (115-139) for affected and 119 (110-131) for nonaffected, and after treatment it decreased to 88 (75-99) for affected and 109 (100-119) for nonaffected (Table 1).

Genome-Wide Association Study

Of 433 saliva samples received, 8 failed to yield high-quality genetic data. After quality control filtering, a total of 411 patients and 623,289 SNPs were eligible for GWAS (Supplementary Figures 1 and 2, available online).

There was no indication of population stratification or inflation in the quantile-quantile plot of observed vs expected -log_{10} (P values) (Supplementary Figure 5, available online). GWAS controlling for cisplatin-based chemotherapy dosage identified 17 SNPs associated with GFR decline. Seven SNPs located...
contiguous on chromosome 14 within the intergenic region between LINC00645 and FOXG1 passed a genome-wide statistical significance threshold of $P = 8.02 \times 10^{-8}$ (Figure 2; Table 2). Nine additional SNPs located on chromosome 8, cytoband p22, passed a suggestive threshold of $P = 1 \times 10^{-5}$ and were located in the intron and 3’ untranslated region of NAT1 or the intergenic region between NAT1 and NAT2. SNP rs17038909 ($P = 6.70 \times 10^{-5}$), located in the intergenic region between CNTN6 and CNTN4, passed the genome-wide statistical significance threshold.

These 17 SNPs were included in input feature space of the machine learning models.

### Risk Prediction Model

A baseline predictive model with only clinical features was trained using random forests. Of the initial 10 clinical features, 6 features were prioritized through recursive backwards elimination (Figure 1A): age at time of treatment, GFR before treatment, cumulative cisplatin-dose per square meter of BSA, number of treatment cycles, prognostic classification as per IGCCCG (1), stage of the disease, excluding group and histology. Univariate analysis also highlighted features selected in the random forest model (Table 1).

### SNPs and Clinical-Based Model

A selection of genomic markers was added to the baseline clinical prediction model: 17 SNPs from the GWAS and 4 additional SNPs from prior literature. Through recursive backwards elimination, 15 features were prioritized (6 clinical and 9 SNPs). The selected SNPs were rs11615 and rs3212986 (ERCC1), rs13181 (ERCC2), rs4986993 (NAT1), rs15561 (NAT1), rs136019 (SLC22A2), and rs17038909 (CNTN6/CNTN4) (Figure 1, B and C). None of the SNPs located within the intergenic region between LINC00645 and FOXG1 were selected.

By adding genomic markers, ROC-AUC increased from 0.635 (95% confidence interval [CI] = 0.629 to 0.640) to 0.731 (95% CI = 0.726 to 0.736) (Figure 1D for additional performance metrics).
Additionally, 2 PRS were added independently to the baseline clinical model but did not outperform the individual SNPs (Supplementary Table 1, available online).

**Model Robustness**

As a further validation, we tested for random outcome, simulated by permuting the labels 2000 times. This generated random performance for the model based on the clinical traits in combination with the 9 SNPs previously reported, with a ROC-AUC mean of 0.498 (95% CI = 0.497 to 0.500). Furthermore, to assess if the SNP selection was meaningful, the performance of 9 random GWAS SNPs instead of the previously described 9 selected SNPs was tested when combined with the selected clinical traits; this process was repeated 2000 times. This performed very similarly to clinical traits alone, with a ROC-AUC mean of 0.661 (95% CI = 0.660 to 0.661) against the model scores with a ROC-AUC mean of 0.742 (95% CI = 0.741 to 0.743) (Figure 3).
Replication Dataset

The holdout set (78 individuals: 20 nephrotoxicity affected) was used for replication of the random forest models with clinical and genetic features. A ROC-AUC of 0.692 (95% CI = 0.688 to 0.696) was obtained on the final evaluation (Figure 4A).

A prediction cutoff of 0.90 and 0.30 for high risk and low risk, respectively, of developing nephrotoxicity was chosen for further analysis on 1 validation external set to discuss the model clinical utility. A random forest score between 0.30 and 0.90 was not enough to make a clinical decision. In the high-risk group, we had a positive predictive value of 0.67 (33% false discovery rate) and specificity of 0.99 while capturing 6% of all nephrotoxicity, whereas in the low-risk group we had a sensitivity of 0.92 and negative predictive value of 0.92 (8% false omission rate), which captured 32% of all nonaffected patients (Figure 4B).

Discussion

In this study, we were able to predict patients at risk of developing nephrotoxicity after BEP chemotherapy based on clinical and genetic features with a machine learning algorithm. Clinical features selected on the random forests–driven baseline clinical model were known risk factors of renal toxicity (2) and were statistically significant in univariate analysis. The aim of the baseline model was to mimic and codify clinical intuition, which relies on the available clinical information at the time of treatment.

When genomic markers were added to the baseline model, prediction power substantially improved. We believe that genomic information, although not being predictive on its own, improves a baseline clinical model for identification of patients at risk for nephrotoxicity.

PRS did not perform as well as independent SNPs when added to the model, suggesting that nonlinear correlations between SNPs drove the increase in performance opposed to the linear combination that PRS offer, as has also been suggested elsewhere (26).

SNPs located in the LINCO00645 and FOXG1 intergenic regions, although strongly associated in the GWAS (P = 5 × 10⁻⁸), were not selected in the machine learning model because of either limited contribution or low minor allele frequencies (Table 2) that made it harder to detect in cross-validated setups.

SNPs rs4986993, rs15561, and rs8190870 (NAT1), rs1353035 (NAT1/NAT2), and rs17038909 (CNTN6/CNTN4) were newly discovered in the present GWAS to be associated with nephrotoxicity and added performance to the machine learning model.

NAT1 and NAT2 encode for arylamine N-acetyltransferases that take part in metabolizing drugs and chemical compounds in humans with a role in folate metabolism (27). These 2 genes encode similar protein sequences [identity = 81.03%, Clustal-Omega, Uniprot (28)], yet differ on expression profiles (13). NAT1 is ubiquitously expressed in the central nervous system, and NAT2 is specifically expressed in the liver, colon, and small intestine (Supplementary Figure 6, available online). It has been reported that cisplatin can impair NAT1 by blocking its transferase activity in human breast cancer cells and impair murine Na⁺-ATPase activity in cultured mouse tissues (liver and kidney) (29), which on one hand contributes to the therapeutic effects of cisplatin, but on the other hand may lead to accumulation of cisplatin in the kidneys.

CNTN6 and CNTN4 encode for contacting proteins, which mediate cell surface interactions during nervous system development and have been suggested to be associated with neurodevelopmental disorders (30–32), though the association with nephrotoxicity needs to be further explored. SNPs found previously to be associated with nephrotoxicity were incorporated in this model. These SNPs were located at ERCC1, ERCC2, and SLC22A2.

ERCC1 and ERCC2 encode for excision repair proteins, and polymorphisms in ERCC1/2 have been reported to alter ERCC1/2 DNA repair function (33–35), which may affect nephron repair capacity after cisplatin exposure during chemotherapy (36–39). If not adequately repaired, cisplatin-induced DNA damage can induce cell death (40,41).
TOP GWAS HITS AND LITERATURE SNP HITS FOR CISPLATIN-BASED NEPHROTOXICITY IN TESTICULAR CANCER PATIENTS

| SNP       | Gene         | CHR | Position | Region/Consequence | Alleles (ref/alt) | MAF (all) | MAF (EUR) | P     |
|-----------|--------------|-----|----------|--------------------|-------------------|-----------|-----------|-------|
| rs17038909| CNTN6, CNTN4 | 3   | 1461745  | Intergenic         | A/G               | G: 0.10   | G: 0.08   | 6.70 × 10⁻⁸ |
| rs8190845 | NAT1         | 8   | 18078628 | Intronic           | G/A               | A: 0.20   | A: 0.15   | 1.79 × 10⁻⁶ |
| rs155561  | NAT1         | 8   | 18080651 | 3 UTR              | A/C               | A: 0.44   | A: 0.28   | 2.29 × 10⁻⁷ |
| rs4986993 | NAT1         | 8   | 18080747 | 3 UTR              | T/G               | T: 0.44   | T: 0.28   | 5.25 × 10⁻⁷ |
| rs8190870 | NAT1         | 8   | 18081272 | Downstream         | C/T               | T: 0.14   | T: 0.15   | 1.12 × 10⁻⁶ |
| rs13270094| NAT1, NAT2   | 8   | 18082354 | Intergenic         | G/A               | A: 0.08   | A: 0.13   | 7.64 × 10⁻⁶ |
| rs13277177| NAT1, NAT2   | 8   | 18086096 | Intergenic         | A/G               | G: 0.06   | G: 0.10   | 9.72 × 10⁻⁶ |
| rs13277481| NAT1, NAT2   | 8   | 18086217 | Intergenic         | A/G               | G: 0.08   | G: 0.13   | 5.47 × 10⁻⁶ |
| rs13270961| NAT1, NAT2   | 8   | 18139163 | Intergenic         | T/C               | C: 0.08   | C: 0.11   | 7.31 × 10⁻⁶ |
| rs1353035 | NAT1, NAT2   | 8   | 18140633 | Intergenic         | C/T               | C: 0.15   | C: 0.17   | 5.35 × 10⁻⁶ |
| rs17095485| LINC00645, FOXG1 | 14 | 28500775 | Intergenic         | G/T               | T: 0.07   | T: 0.06   | 1.13 × 10⁻⁸ |
| rs17382424| LINC00645, FOXG1 | 14 | 28529219 | Intergenic         | G/T               | T: 0.02   | T: 0.06   | 1.29 × 10⁻⁸ |
| rs4551947 | LINC00645, FOXG1 | 14 | 28584430 | Intergenic         | C/A               | A: 0.05   | A: 0.06   | 2.26 × 10⁻⁸ |
| rs8020589 | LINC00645, FOXG1 | 14 | 28604708 | Intergenic         | C/T               | T: 0.07   | T: 0.06   | 1.44 × 10⁻⁸ |
| rs10131751| LINC00645, FOXG1 | 14 | 28681216 | Intergenic         | C/A               | A: 0.07   | A: 0.07   | 1.45 × 10⁻⁸ |
| rs9671720 | LINC00645, FOXG1 | 14 | 28714229 | Intergenic         | C/T               | T: 0.05   | T: 0.04   | 8.81 × 10⁻⁹ |
| rs12323487| LINC00645, FOXG1 | 14 | 28837771 | Intergenic         | C/A/T             | A: 0.09   | A: 0.05   | 1.19 × 10⁻⁸ |

SLC22A2 encodes for organic cation transporter 2 (OCT2) protein, which is expressed in the proximal tubule epithelial cells of the kidney and involved in the absorption and excretion of xenobiotics and metabolites (42). OCT2 efficiently mediates cisplatin cellular uptake, leading to high cisplatin accumulation in renal proximal tubule cells (43) where cisplatin-induced nephrotoxicity typically occurs (44). OCT2 may be a key regulator in the renal accumulation of cisplatin, affecting drug handling and inducing nephrotoxicity (42,45).

During primary treatment of disseminated testicular cancer, about one-third of the patients develop cisplatin-induced nephrotoxicity (46,47).

This clinical and genomics-based model could be used as an early assessment for nephrotoxicity risk, assisting in identifying patients at high and low nephrotoxicity risk and influencing decisions on cisplatin chemotherapy cycles.

Using a 0.50 cutoff on the random forest model scores, we were able to achieve a sensitivity of 0.65, positive predictive value of 0.35, specificity of 0.60, and negative predictive value of 0.83. Differential thresholding of the nephrotoxicity model classified patients into high, low, and intermediate risk. For the high-risk group, the model correctly classified 67% of the patients who developed nephrotoxicity, yet only a small fraction of affected individuals was captured (0.06 sensitivity). On the other hand, for the low-risk group, the model correctly classified 92% of the patients who did not develop nephrotoxicity and captured 32% of the nonaffected population (Figure 4B).

Even though the model shows utility in the ability to predict toxicity throughout the score range, extreme cutoffs to identify the highest and lowest risk patients could point at the least disruptive implementation of such a model within current practice.

A strength of this study is the large dataset with a good representation of patients who developed nephrotoxicity after cisplatin-based chemotherapy, using exact renal measurements, and the first application, to our knowledge, of artificial intelligence on predicting such a phenotype.

The machine learning models appeared to be robust with stable performance across 100 random cross-validation splits of the training data, demonstrating performance of 0.731 mean ROC-AUC in cross-validation and 0.692 (95% CI = 0.688 to 0.696) ROC-AUC in the holdout set. Yet, as a limitation, the machine learning setups use some of the association results from the GWAS on the same cohort; therefore, replication on another cohort from an external dataset would be of substantial interest. NAT1 and NAT2 appear as interesting genetic targets to prioritize for assaying in future nephrotoxicity studies and would benefit from functional validation.

The ability to develop machine learning models for patient stratification in different nephrotoxicity risk groups has the potential to balance aggressive treatment against predicted toxicity risk.

In the future, toxicity may play a larger role in guiding treatment across several complex diseases, where data-driven prediction models may aid in decision making. Some of the clinical features used in this model, such as age at the time of treatment and GFR before chemotherapy as well as some of the identified genomics markers, could be applicable to other tumors types. Cisplatin is one of the most compelling drugs used in cancer treatment, and nephrotoxicity is a well-known side effect from its use. Our model could be applicable to ovarian, bladder, and lung cancer, where more elderly patients are at risk of nephrotoxicity and early identification of toxicity risks (or lack thereof) may influence treatment aggression or increase monitoring for selected patients.
Funding
This work was supported by the Danish cancer society (R40-A2119). SLG was supported by Idella Foundation. ZZ and RLN were supported by Sino-Danish Center for Education and Research.

Notes
Role of the funder: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit.

Conflicts of interest: RG is employed with Novo Nordisk
Conflicts of interest:

References
1. Diliba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103–1124.
2. Lauritzen J, Mortensen MS, Kier MGU, et al. Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol. 2015;26(1):173–178.
3. Fung C, Fossa SD, Williams A, Travis LB. Long-term morbidity of testicular cancer treatment. Urol Clin North Am. 2015;42(3):393–408.
4. Dasari S, Tchounouw PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
5. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(12):1226–1234.
6. Karasawa T, Stryger FS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219–227.
7. Nematbakhsh M, Pezeshki Z, Eshraghi Jazi F, et al. Cisplatin-induced nephrotoxicity, protective supplements and gender differences. Asian Pac J Cancer Prev. 2017;18(2):295–314.
8. Achkar JW, Abdulshamyn N, Ali-Sultani H, Joseph JM, Uddin S, Mrafei F. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018;16(1):96.
9. Zazuli Z, Vijeerberg S, Slob E, et al. Genetic variations and cisplatin nephrotoxicity: a systematic review. Eur J Pharmacol. 2015;740:364–378.
10. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Mol Pharmacol. 2008;73(suppl 1):e478s.
11. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–575.
12. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(6):e164.
13. Lonsdale J, Thomas J, Salamone M, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):S80–S85.
14. MacArthur D, Bowler E, Cerezo M, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. 2017;45(D1):D896–D901. doi: 10.1093/nar/gkw1133
15. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. BMJ. 1995;310(6937):170–171.
16. International Germ Cell Cancer Collaborative Group. Germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594–603.
17. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
18. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12:2825–2830.
19. Chen Y-C, Weng S-C, Liu J-S, Chuang H-L, Hsu C-C, Tamg D-C. Severe decline of estimated glomerular filtration rate associates with progressive cognitive deterioration in the elderly: a community-based cohort study. Sci Rep. 2017;7(1):42600.
20. Cheng T-Y, Wen S-F, Astor BC, Tao XG, Samet JM, Wen CP. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am J Kidney Dis. 2008;52(5):1051–1060.
21. Picard RR, Berk KN. Data splitting: Am Stat. 1990;44(4):140–147.
22. Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006;7(1):91.
23. Lai C, Guo S, Cheng L, Wang W. A comparative study of feature selection methods for the discriminative analysis of temporal lobe epilepsy. Front Neural. 2017;8:633.
24. Euesden J, Lewis CM, O’Reilly P. PRSice: Polygenic Risk Score software. Bioinformatics. 2015;31(9):1466–1468.
25. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45–50.
26. Ho DSW, Schierding W, Wake M, Saffery R, O’Sullivan J. Machine learning SNP-based prediction for precision medicine. Front Genet. 2019;10:267.
27. Sim E, Abouhamad A, Ryan A. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol. 2014;171(11):2705–2725.
28. Consortium TU. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2018;47(D1):D506–D515.
29. Ragunathan N, Dairou J, Pluviance B, et al. Identification of the xenobiotic-metabolising enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol. 2008;74(4):1761–1768.
30. Huj I, Liao J, Sathasso M, et al. CNTN6 copy number variations in 14 patients: a possible candidate gene for neurodevelopmental and neuropsychiatric disorders. J Neurol Disord. 2015;7(1):26.
31. Mercati O, Huguet G, Danckaert A, et al. CNTN6 mutations are risk factors for abnormal auditory sensory perception in autism spectrum disorders. Mol Psychiatry. 2017;22(4):625–633.
32. Tassano E, Uccella S, Giacomini T, et al. Clinical and molecular characterization of two patients with CNTN6 copy number variations. Cytogenet Genome Res. 2018;156(3):144–149.
33. Ni M, Zhang W, Qiu J, et al. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in the Chinese population. Sci Rep. 2015;4(1):4112.
34. Yang L, Ritchie A-M, Melton DW. Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1. Oncotarget. 2017;8(33):55246–55264.
35. Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010:1–16.
36. Khurin A V, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10(1):54–61.
37. Tvetkov MV, Behrens G, O’Brien VP, Hofloh K, Brockmüller J, Benöhr P. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics. 2011;12(10):1417–1427.
38. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17(6):463–469.
39. Windsor RE, Strauss K, Jollis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012;118(7):1856–1867.
40. Zambe DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20(10):435–439.
41. Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck C. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018;73(suppl 1):e478s.
42. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10(11):2039–2049.
43. Giarmobili G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced ototoxicity in mouse kidney and apical accumulation in renal proximal tubule cells. Kidney Int. 1995;48(3):761–770.
44. Filipski KK, Losos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14(12):3875–3880.
45. Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.

Downloaded from https://academic.oup.com/jncics/article/4/3/pkaa032/5824303 by Novo Nordisk A/S user on 28 September 2020